ArticleFrontiers in cellular and infection microbiology2026
Role of the gut-lung axis in sepsis and the effect of probiotics on pulmonary complications.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sepsis is a major cause of mortality and organ failure, particularly associated with pulmonary complications. This study investigates the role of the gut-lung axis in sepsis-induced lung injury and explores the therapeutic potential of the probiotic Lactobacillus rhamnosus GG in improving these effects. Methods: Using a cecal ligation and puncture (CLP) model in male Wistar rats, we assessed pulmonary function, histopathology, and inflammation. Twenty-four animals were randomly assigned into four groups (n = 8/group): Control, Sepsis, Probiotic, and Sepsis + Probiotic. Lactobacillus rhamnosus GG (2 × 10⁸ CFU/day) was administered orally for seven days. Pulmonary function was assessed using whole-body plethysmography and flexiVent, while lung histopathology and fibrosis were evaluated using hematoxylin and eosin and Masson's trichrome staining. Inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-10) were quantified by ELISA, gut microbiota composition was analyzed by 16S rRNA sequencing, and arterial blood gas and hemodynamic parameters were recorded. Results: Sepsis significantly impaired pulmonary function, characterized by reduced tidal volume and lung compliance, increased respiratory rate, hypoxemia, hypercapnia, metabolic acidosis, hypotension, and tachycardia (p < 0.01). Peripheral neutrophil and macrophage counts were elevated, and severe gut dysbiosis was observed, marked by reduced microbial diversity and increased Proteobacteria abundance. Probiotic treatment significantly improved pulmonary mechanics and lung histology compared to untreated septic animals. Probiotic supplementation also restored gut microbiota diversity, reduced pro-inflammatory cytokines, and enhanced anti-inflammatory responses. Discussion: These results suggest that Lactobacillus rhamnosus GG acts via the gut-lung axis to alleviate sepsis-induced pulmonary dysfunction, supporting its potential as an adjunctive therapy for sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.